PUBLIC COMPANY
save$LBRXLB PHARMACEUTICALS INC
$LBRX47.77+7.92%New York, NY, USupdated 7h ago
community read0 votes
pipeline
3
marketed
1
phase 3
1
catalysts ytd
7
approvals ytd
0
recalls ytd
5
Pipeline(3)
pipeline depth3 products
1Preclinical1Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
- phase352-week Open Label Safety-Tolerability Study
- phase3Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- phase2Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Mar 6, 26grantLenz Robert A. · 20,000 sh
🐶 Hiring Signal
News
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.biopharma_dive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that